Another study tested the HIF-1α inhibitor YC-1 in combination with BNCT and showed that this was able to sensitise hypoxic tumour glioblastoma and oral squamous cell carcinoma cells to the effects of BPA-mediated BNCT by ~1.7- and ~3.4-fold, respectively, possibly due to an increased expression in LAT1 following HIF-1α inhibition, enabling a greater uptake of BPA [79]. The gene discussed is HIF1A; the disease is neoplasm.